Compare AstraZeneca plc (AZN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? AstraZeneca plc trades at $158.67 (market cap $248.14B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: AstraZeneca plc pays a 2.01% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and AstraZeneca plc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| AZN | YMAX | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $13.26 |
52-Week Low | $147.06 | $7.27 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
YMAX trades at $7.635, down 0.97% on the day, with a bullish technical signal but bearish moving averages. The ETF shows a pattern of weekly dividend distributions, though recent payouts have decreased from $0.15 to $0.06, indicating potential income pressure. Key technical levels show support at $7 and resistance at $8, with RSI suggesting mild overbought conditions.
The outlook for YMAX hinges on its ability to sustain distributions amid cost concerns. Risks include the fund-of-funds fee structure and market volatility. Analyst sentiment is mixed, with some highlighting income appeal but cautioning on expense drag. Upside depends on stable option income generation in varying market regimes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
